Molecular Inflammation Board at the Center for Personalized Medicine
NCT ID: NCT07132333
Last Updated: 2025-08-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
3000 participants
OBSERVATIONAL
2022-11-16
2032-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Flemish Joint Effort for Biomarker PRofiling in Inflammatory Systemic Diseases
NCT05670301
Development and Characterization of Functional Assays for the Analysis of Inflammation Signaling Pathways
NCT06971289
Evaluation and Long-Term Follow-up of Patients With Inflammatory Disorders
NCT00001351
Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
NCT07251179
Trauma as a Trigger for Autoimmunity
NCT03767712
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study objectives are:
To ensure a prospective documentation of all patients who are referred to the Molecular Inflammation Board in routine clinical care To prospectively ensure the documentation of MEB patients with an emphasis to clinical outcome parameters and further response assessments (e.g. peripheral immunmonitoring, imaging parameters) To prospectively assess patient-reported outcome of MEB patients To evaluate compliance to MEB suggestions in routine clinical care
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biologic Agent
Intervention with biologic agents
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Given informed consent
* 18 years of age
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Freiburg
OTHER
University Hospital Heidelberg
OTHER
University Hospital Ulm
OTHER
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Tübingen - Center for Personalized Medicine
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
482/2022BO1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.